HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 16, 10706-10714, April 21, 2006

This Article Full Text Full Text (PDF) All Versions of this Article: 281/16/10706    most recent M513415200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shen, J. Articles by Zhu, Z. Search for Related Content PubMed PubMed Citation Articles by Shen, J. Articles by Zhu, Z. Social Bookmarking                      What's this?

Single Variable Domain-IgG Fusion

A NOVEL RECOMBINANT APPROACH TO Fc DOMAIN-CONTAINING BISPECIFIC ANTIBODIES^*

From the Department of Antibody Technology, ImClone Systems Inc., New York, New York 10014

Both laboratory and early clinical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially significant application in cancer therapy. The clinical development of BsAb as therapeutics has been hampered, however, by the difficulty in preparing the materials in sufficient quantity and quality by traditional methods. In recent years, a variety of recombinant methods has been developed for efficient production of BsAb, both as antibody fragments and as full-length IgG-like molecules. Here we describe a novel recombinant approach for the production of an Fc domain-containing, IgG-like tetravalent BsAb, with two antigen-binding sites to each of its target antigens, by genetically fusing a single variable domain antibody to the N terminus of the light chain of a functional IgG antibody of different specificity. A model BsAb was constructed using a single variable domain antibody to mouse platelet-derived growth factor receptor and a conventional IgG antibody to mouse vascular endothelial growth factor receptor 2. The BsAb was expressed in mammalian cells and purified to homogeneity by one-step protein A affinity chromatography. Furthermore, the BsAb retains the antigen binding specificity and the receptor neutralizing activity of both of its parent antibodies. This design and expression of Fc domain-containing, IgG-like BsAb should be applicable to the construction of similar BsAb from antibodies recognizing any pair of antigens.

Received for publication, December 16, 2005 , and in revised form, February 14, 2006.

^* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence and reprint requests may be addressed: ImClone Systems Inc., 180 Varick St., New York, NY 10014. Tel.: 212-645-1405; Fax: 212-645-2054; E-mail: juqun.shen{at}imclone.com. ² To whom correspondence and reprint requests may be addressed. Tel.: 212-645-1405; Fax: 212-645-2054; E-mail: zhenping.zhu{at}imclone.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, and C.-H. Chang Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood, June 11, 2009; 113(24): 6161 - 6171. [Abstract] [Full Text] [PDF]

				E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, Y. Wang, and C.-H. Chang Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics Cancer Res., October 15, 2008; 68(20): 8384 - 8392. [Abstract] [Full Text] [PDF]